Gut microbiome in hemodialysis patients treated with calcium acetate or treated with sucroferric oxyhydroxide: a pilot study
Por:
Merino-Ribas, A, Araujo, R, Bancu, I, Graterol, F, Vergara, A, Noguera-Julian, M, Paredes, R, Bonal, J and Sampaio-Maia, B
Publicada:
1 ago 2022
Ahead of Print:
1 dic 2021
Resumen:
Purpose It has been proved that the gut microbiome is altered in patients with chronic kidney disease. This contributes to chronic inflammation and increases cardiovascular risk and mortality, especially in those undergoing hemodialysis. Phosphate binders may potentially induce changes in their microbiome. This trial aimed to compare the changes in the gut microbiome of hemodialysis patients treated with calcium acetate to those treated with sucroferric oxyhydroxide. Methods Twelve hemodialysis patients were distributed to receive calcium acetate or sucroferric oxyhydroxide for 5 months. Blood samples (for biochemical analysis) and stool samples (for microbiome analysis) were collected at baseline, 4, 12, and 20 weeks after treatment initiation. Fecal DNA was extracted and a 16S rRNA sequencing library was constructed targeting the V3 and V4 hypervariable regions. Results Regarding clinical variables and laboratory parameters, no statistically significant differences were observed between calcium acetate or sucroferric oxyhydroxide groups. When analyzing stool samples, we found that all patients were different (p = 0.001) among themselves and these differences were kept along the 20 weeks of treatment. The clustering analysis in microbial profiles grouped the samples of the same patient independently of the treatment followed and the stage of the treatment. Conclusion These results suggest that a 5-month treatment with either calcium acetate or sucroferric oxyhydroxide did not modify baseline diversity or baseline bacterial composition in hemodialysis patients, also about the high-variability profiles of the gut microbiome found among these patients.
Filiaciones:
Merino-Ribas, A:
Univ Autonoma Barcelona, Barcelona, Spain
Hosp Badalona Germans Trias & Pujol, Nephrol Dept, Badalona, Spain
Hosp Univ Girona Doctor Josep Trueta, Nephrol Dept, Avinguda Franca S-N, Girona 17007, Spain
Univ Porto, i3S Inst Invest & Inovacao Saude, Porto, Portugal
Araujo, R:
Univ Porto, i3S Inst Invest & Inovacao Saude, Porto, Portugal
:
Univ Autonoma Barcelona, Barcelona, Spain
Hosp Badalona Germans Trias & Pujol, Nephrol Dept, Badalona, Spain
:
Univ Autonoma Barcelona, Barcelona, Spain
Hosp Badalona Germans Trias & Pujol, Nephrol Dept, Badalona, Spain
Vergara, A:
Hosp Badalona Germans Trias & Pujol, IrsiCaixa AIDS Res Inst, Barcelona, Spain
:
Hosp Badalona Germans Trias & Pujol, IrsiCaixa AIDS Res Inst, Barcelona, Spain
:
Hosp Badalona Germans Trias & Pujol, IrsiCaixa AIDS Res Inst, Barcelona, Spain
:
Hosp Badalona Germans Trias & Pujol, Nephrol Dept, Badalona, Spain
Sampaio-Maia, B:
Univ Porto, i3S Inst Invest & Inovacao Saude, Porto, Portugal
Univ Porto, Fac Dent Med, Porto, Portugal
hybrid
|